GSK's Massive Study: Could Shingles Vaccine Cut Dementia Risk?

GSK is conducting a study involving over a million older adults in the UK to determine if its shingles vaccine, Shingrix, lowers dementia risk. The study utilizes NHS health data and naturally occurring patient groups due to an expanded vaccination program, providing insight into potential causal links.

In a groundbreaking endeavor, GSK is investigating whether its Shingrix vaccine, primarily used against shingles, may also reduce the risk of dementia.

The British pharmaceutical company is accessing data from over a million UK citizens aged 65 to 66. This study takes advantage of the NHS's extensive database, allowing examination of naturally randomised patient groups formed by changes to the national vaccination program. Previously, only those 70 and older could receive the vaccine, but recent policy shifts permit 65-year-olds access while those slightly older must wait.

This unique natural trial setting provides a rare opportunity for scientists to explore potential causal links between shingles vaccination and dementia prevention, a connection previously established by association rather than causation. The study, involving the UK Dementia Research Institute, could lead to significant discussions with regulators for an expanded vaccine label if findings prove conclusive.

(With inputs from agencies.)